Free Newsletter
Barr, Teva merger poised for tax-free status
The tax gods were with Barr Pharmaceuticals and Teva Pharmaceutical Industries: They recently cleared some IRS requirements to have their merger deal defined as a reorganization with tax-free status.
That's quite a boon for Teva and Barr, who started the merger process in July. Barr stock will be converted into 0.6272 shares of Teva stock plus $39.60 in cash. New Jersey-based Barr will become a domestic subsidiary of Jeruselum-based Teva and the deal is expected to close later this year.
To gain tax-free status, the acquisition must meet criteria under Section 368(a)(1)(A) and Section 368(a)(2)(D) of the IRS tax code--in addition to "Helen of Troy" rules related to foreign transactions--but it seems likely it will pass these and other required tests.
Meanwhile, the companies might just need the tax break, as Barr's first quarter results didn't quite hit the mark.
--read about it at Zacks
--see more at CFO.com
Related Articles:
Amgen profits drop, Teva's grow
Teva Pharmaceutical - best Pharma Stocks of 2007
It's Teva plus Barr in a $7.46B buyout
Rumor mill: Teva mulling $7.5B deal for Barr
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact





